Last updated: November 5, 2026
Taytulla is a branded combined oral contraceptive containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, packaged with four ferrous fumarate capsules in a 28-day regimen. FDA approved Taytulla in 2017 under NDA 208304. The product entered a mature, highly competitive contraceptive market and later faced generic substitution, limiting its long-term commercial value. Public company filings do not disclose Taytulla-specific revenue, so its financial trajectory must be assessed through regulatory milestones, patent exposure, generic entry, pricing, and portfolio strategy rather than reported brand sales.
What is Taytulla and how does it compete in the oral contraceptive market?
Taytulla is a low-dose estrogen/progestin oral contraceptive. Its active ingredients are norethindrone acetate and ethinyl estradiol. The product differs from conventional 28-day oral contraceptives by using four ferrous fumarate capsules rather than four hormone-free placebo tablets.
| Attribute |
Taytulla |
| Active ingredients |
Norethindrone acetate and ethinyl estradiol |
| Strength |
1 mg / 20 mcg |
| Dosage form |
Soft gelatin capsules |
| Regimen |
24 active capsules followed by four ferrous fumarate capsules |
| FDA application |
NDA 208304 |
| Original approval |
May 2017 |
| Indication |
Prevention of pregnancy |
| Original developer/marketer |
Warner Chilcott, later associated with Actavis and Allergan |
| Current corporate parent history |
Allergan acquired by AbbVie in 2020 |
| Primary market |
United States |
| Competitive category |
Combined oral hormonal contraceptives |
Taytulla competes with branded products such as Loestrin 24 Fe, Minastrin 24 Fe, Junel Fe, Blisovi Fe, Microgestin Fe, and other norethindrone acetate/ethinyl estradiol products. The therapeutic category has limited differentiation because prescribers can substitute among numerous low-dose combined oral contraceptives.
Taytulla’s commercial positioning depended on three elements: a softgel capsule formulation, a 24-day active-hormone schedule, and the inclusion of iron-containing capsules. Those attributes supported brand marketing but did not create a durable clinical barrier against generic versions with the same active ingredients and regimen.
What FDA regulatory status does Taytulla have?
Taytulla was approved by the FDA on May 2, 2017. The FDA-approved labeling identifies the product as a combined oral contraceptive for prevention of pregnancy in females of reproductive potential.[1]
The product’s regulatory profile is that of a conventional small-molecule oral contraceptive:
- It is approved under an NDA rather than a biologics license application.
- It is subject to abbreviated new drug application, or ANDA, competition.
- It does not receive biosimilar protection because it is not a biologic.
- Its commercial exclusivity depends primarily on patents, labeling restrictions, brand demand, and payer coverage.
- The ferrous fumarate capsules are part of the marketed regimen but do not create biologic exclusivity.
FDA approval did not provide long-term market protection. New chemical entity exclusivity was not the main commercial defense because the product uses established hormonal ingredients rather than a new active pharmaceutical ingredient.
What patents protect Taytulla?
Taytulla’s patent protection centered on formulation and product-combination claims rather than composition-of-matter protection for new chemical entities. The principal publicly associated patent is U.S. Patent No. 9,192,673, which has been cited in litigation and regulatory patent disputes involving Taytulla.[2]
The relevant patent strategy covered aspects of the combined product, including the delivery of norethindrone acetate and ethinyl estradiol in a capsule-based regimen with ferrous fumarate capsules. This type of protection can delay generic competition, but it is generally weaker than a composition-of-matter patent because competitors may challenge claim scope, validity, infringement, or the adequacy of formulation differences.
What formulations are protected by Taytulla patents?
The commercially important formulation characteristics include:
- Soft gelatin capsule delivery.
- Norethindrone acetate and ethinyl estradiol in a low-dose combination.
- A 24-day active-capsule schedule.
- Four ferrous fumarate capsules in the final week of the cycle.
- Packaging and regimen configuration associated with the branded product.
The formulation patents did not prevent ANDA applicants from pursuing generic versions. Generic applicants could challenge listed patents through Paragraph IV certifications or seek approval after patent expiry or settlement-based launch dates.
When does Taytulla lose exclusivity?
Taytulla’s practical exclusivity loss occurred when generic manufacturers obtained FDA approval and commercial access, not merely when the last listed patent reached its expiration date.
The relevant timeline is:
| Event |
Timing |
| FDA approval of Taytulla |
May 2, 2017 |
| Launch of branded product |
2017 |
| Patent litigation and ANDA challenges |
Late 2010s and early 2020s |
| Allergan acquired by AbbVie |
2020 |
| Generic development and FDA approvals |
Early 2020s |
| Broad generic substitution risk |
From the early 2020s onward |
The precise commercial launch date for each generic depends on the ANDA holder, litigation settlement terms, authorized-generic decisions, and state substitution rules. Orange Book patent listings and FDA approval records should be read together because an approved ANDA does not always mean immediate commercial launch.[3]
Taytulla therefore entered the post-exclusivity phase during the early 2020s. Its economic protection was materially weaker than the protection available to a drug with a single, enforceable composition patent.
Which companies are challenging Taytulla and competing with it?
Taytulla has faced competition from both branded contraceptive products and generic manufacturers.
Generic competition
Generic manufacturers have targeted the same active ingredients and dosage regimen. The relevant commercial competitors include companies that have received or pursued ANDA approvals for norethindrone acetate and ethinyl estradiol capsules with ferrous fumarate capsules.
The competitive structure typically includes:
- ANDA applicants challenging listed patents.
- Generic manufacturers waiting for patent expiry or settlement-authorized entry.
- Authorized-generic or branded-generic channels.
- Established contraceptive manufacturers with lower-cost products.
- Retail and mail-order pharmacies substituting lower-priced alternatives.
The market does not require a generic to replicate every aspect of Taytulla’s marketing. Therapeutic substitution can occur when a payer or pharmacist views another norethindrone acetate/ethinyl estradiol product as clinically interchangeable.
Branded competitors
Taytulla competes with other oral contraceptives that have similar hormone combinations or similar dosing schedules. Examples include:
- Loestrin 24 Fe and related products.
- Minastrin 24 Fe.
- Junel Fe.
- Microgestin Fe.
- Blisovi Fe.
- Generics containing norethindrone acetate and ethinyl estradiol.
The largest commercial disadvantage is that many competitors offer lower prices, broad payer coverage, and established prescribing familiarity.
What patent litigation affects Taytulla?
Taytulla-related patent disputes have involved the branded sponsor and generic ANDA applicants. The litigation framework is the Hatch-Waxman process, under which a generic applicant may certify that listed patents are invalid, unenforceable, or not infringed.
A Paragraph IV certification can trigger patent litigation and a potential 30-month FDA approval stay under the Hatch-Waxman Act. The commercial result depends on:
- Whether the patent owner sues within the statutory period.
- Whether the court upholds the asserted claims.
- Whether the generic applicant receives a favorable noninfringement or invalidity ruling.
- Whether the parties settle.
- Whether the settlement permits an agreed launch date.
- Whether multiple ANDA applicants enter at different times.
Publicly reported Taytulla disputes included patent claims associated with formulation and product configuration. These cases were commercially important because a formulation patent can delay generic entry even when the active ingredients themselves are old and widely used.
Did Taytulla have Paragraph IV challenges or settlement agreements?
Taytulla’s generic pathway included patent certifications and litigation risk typical of a branded oral contraceptive with listed formulation patents. Public sources identify patent litigation involving Allergan-related entities and generic applicants, including disputes connected to U.S. Patent No. 9,192,673.[2]
Settlement agreements in pharmaceutical patent cases often establish a permitted generic entry date without a full trial judgment. The commercial effect may include:
- Earlier generic entry than the nominal patent expiration date.
- A launch limited by patent scope.
- A license with no admission of infringement or validity.
- Multiple generic entrants competing after the agreed date.
- Potential authorized-generic arrangements.
The existence of litigation does not by itself establish that Taytulla retained meaningful market exclusivity. Once multiple generic suppliers are available, price compression usually outweighs the value of the original formulation differentiation.
How strong is the Taytulla patent estate?
Taytulla’s patent estate is best characterized as moderate at launch and limited after generic approval.
| Patent-estate factor |
Assessment |
| Active ingredients |
Weak protection because both hormones are established |
| Composition-of-matter protection |
None of the type associated with a new chemical entity |
| Formulation protection |
Material but challengeable |
| Dosage-regimen protection |
Potentially useful, subject to claim construction and validity |
| Manufacturing complexity |
Low to moderate |
| Generic design-around risk |
Moderate to high |
| Biosimilar barrier |
Not applicable |
| Post-approval lifecycle protection |
Limited |
The strongest commercial defense was the combination of formulation, packaging, and litigation delay. The weakest defense was the absence of a novel active ingredient and the presence of many clinically substitutable contraceptives.
What is the Orange Book status of Taytulla?
Taytulla was listed in the FDA Orange Book as an NDA product with associated patent information. Orange Book listings inform ANDA applicants which patents the sponsor asserts against generic versions.[3]
The key business implications are:
- Listed patents can create a litigation pathway under Hatch-Waxman.
- Orange Book listing does not guarantee patent validity.
- A generic applicant can certify that a patent will not be infringed, is invalid, or is unenforceable.
- Orange Book status does not reveal the commercial terms of a settlement.
- Patent listings should be reconciled with current FDA approval records and court dockets.
Taytulla’s Orange Book protection was therefore a procedural and litigation asset, not a permanent market barrier.
How did Taytulla’s financial trajectory develop?
Taytulla was launched into a large but price-sensitive contraceptive market. The product likely generated commercial value through branded prescriptions, insurance reimbursement, and differentiation from older tablet formulations. Public filings from Allergan and AbbVie do not report Taytulla revenue as a separate line item.[4][5]
Its financial trajectory can be divided into four stages.
1. Launch and formulary development: 2017 to approximately 2019
The launch phase depended on physician adoption, payer access, and the ability to secure coverage despite the availability of lower-cost alternatives. Marketing emphasized the capsule format and 24 active-pill regimen.
Revenue at this stage was likely concentrated in branded prescriptions and manufacturer-supported access programs. The product did not have the scale or pricing power associated with a major specialty drug or protected chronic therapy.
2. Patent-defense phase: approximately 2019 to 2021
Patent litigation and generic development became central to the product’s value. During this period, the sponsor’s economic objective was to delay generic entry and preserve branded reimbursement.
The acquisition of Allergan by AbbVie in 2020 transferred Taytulla into a larger portfolio. AbbVie’s public reporting grouped products into broad business segments and did not provide a separate Taytulla revenue series.[5]
3. Generic-entry phase: early 2020s
Once FDA-approved generic alternatives became available, Taytulla faced three forms of erosion:
- Lower average selling prices.
- Pharmacy-level substitution.
- Payer pressure toward generic norethindrone acetate/ethinyl estradiol products.
The presence of multiple generic manufacturers typically causes rapid net-price deterioration. Brand prescriptions may persist among patients who prefer Taytulla or receive it through favorable coverage, but those prescriptions generally become less profitable.
4. Mature or declining phase: mid-2020s
Taytulla’s residual value depends on brand loyalty, supply continuity, payer placement, and whether the sponsor continues active promotion. The product’s financial profile is likely a declining branded tail rather than a growth asset.
The absence of separately reported revenue prevents a reliable dollar estimate. The appropriate valuation approach is to model:
- Remaining branded prescription volume.
- Net price after rebates.
- Generic substitution rate.
- Patient assistance expense.
- Promotional spending.
- Manufacturing and distribution costs.
- Any licensing or settlement payments.
- Probability of continued commercial availability.
What generic launch risks exist for Taytulla?
Generic launch risk is high because the product uses established active ingredients and has a commercially replicable dosage regimen.
The main generic-entry scenarios are:
| Scenario |
Market effect |
| Single generic launch |
Moderate price erosion and gradual substitution |
| Multiple simultaneous launches |
Rapid price compression |
| Authorized-generic launch |
Greater control over channel pricing but lower branded sales |
| Delayed generic launch |
Temporary preservation of brand revenue |
| Reformulated generic or therapeutic substitute |
Broader payer-driven erosion |
| Generic supply disruption |
Temporary recovery in branded demand |
The main remaining barriers are regulatory approval, patent litigation, manufacturing validation, softgel production, and commercial distribution. None is likely to support long-term exclusivity comparable to a novel-molecule patent.
What manufacturing and intellectual-property barriers apply to Taytulla?
Taytulla’s softgel dosage form creates more manufacturing complexity than a standard compressed tablet. A generic manufacturer must establish:
- Equivalent active-ingredient content.
- Appropriate dissolution and stability.
- Softgel encapsulation controls.
- Compatibility of the hormonal ingredients with excipients.
- Consistent ferrous fumarate capsule production.
- Packaging and labeling compliance.
- Bioequivalence under FDA requirements.
These factors may delay smaller manufacturers, but they do not create a durable barrier for established generic companies with softgel capabilities. The formulation is technically manageable compared with sterile injectables, inhaled products, complex biologics, or controlled-release implants.
How does Taytulla compare with competing contraceptives?
| Product type |
Differentiation |
Generic exposure |
Commercial outlook |
| Taytulla |
Softgel, 24 active capsules, ferrous fumarate |
High after generic approval |
Declining branded tail |
| Loestrin-type products |
Similar hormone combination |
High |
Mature and price-sensitive |
| Generic norethindrone acetate/ethinyl estradiol |
Low-cost equivalent category |
Immediate by design |
Strong payer preference |
| Long-acting reversible contraceptives |
Different delivery and adherence profile |
Lower in some products |
More durable brand economics |
| Progestin-only products |
Different safety and clinical profile |
Varies |
Segment-specific growth |
| Transdermal and vaginal products |
Nonoral delivery |
Product-specific |
Differentiation depends on device and patent estate |
Taytulla’s differentiation is weaker than that of a device-based contraceptive or a product with a proprietary delivery system. Its competitive position is also vulnerable to formulary substitution.
What are the licensing and transaction implications for Taytulla?
No major standalone licensing transaction for Taytulla has been publicly disclosed as a central value driver. The product changed corporate context through Allergan’s acquisition by AbbVie, but that was a company-level transaction rather than a Taytulla-specific licensing deal.[5]
For licensing or acquisition analysis, Taytulla should be valued as a late-life branded product. Key diligence items include:
- Current NDA ownership and marketing status.
- Orange Book patent listings.
- ANDA approvals and launch dates.
- Patent litigation settlements.
- Supply and manufacturing agreements.
- Brand distribution rights.
- Any authorized-generic arrangement.
- Net sales by channel.
- Gross-to-net deductions.
- Product liability and regulatory obligations.
The most material transaction risk is that reported prescription volume may overstate economic value after generic substitution and rebate pressure.
Key Takeaways
- Taytulla is a 2017 FDA-approved combined oral contraceptive containing norethindrone acetate and ethinyl estradiol.
- Its value came from formulation and regimen differentiation, not a novel active ingredient.
- U.S. Patent No. 9,192,673 was central to the publicly associated patent strategy.
- Paragraph IV litigation and formulation patents delayed or managed generic competition but did not create durable exclusivity.
- FDA-approved generic competition emerged in the early 2020s, creating substantial price and volume pressure.
- AbbVie and Allergan public filings do not disclose Taytulla-specific revenue.
- The product’s financial trajectory is best modeled as launch growth, patent-defense stabilization, generic erosion, and a declining branded tail.
- Biosimilar risk is irrelevant because Taytulla is a small-molecule drug, not a biologic.
- Manufacturing complexity is moderate because of the softgel format, but it is not a durable barrier for established generic manufacturers.
- Taytulla’s residual commercial value depends on brand retention, payer coverage, supply reliability, and generic substitution rates.
FAQs About Taytulla Patent and Market Risk
Is Taytulla still a protected brand-name contraceptive?
Taytulla remains a branded product, but its meaningful commercial exclusivity has been reduced by generic competition and the age of its formulation patents.
Does Taytulla have biosimilar competition?
No. Biosimilars apply to biologic products. Taytulla is a conventional small-molecule oral contraceptive and faces ANDA-based generic competition instead.
What is the generic version of Taytulla?
The generic is generally described as norethindrone acetate and ethinyl estradiol capsules, with ferrous fumarate capsules, in the 1 mg/20 mcg strength and 24-plus-four regimen.
Can pharmacies automatically substitute a generic for Taytulla?
Substitution depends on state pharmacy law, the product’s therapeutic-equivalence rating, payer requirements, and the prescriber’s instructions.
Is Taytulla a high-value pharmaceutical asset?
Taytulla is more likely to be valued as a mature branded cash-flow product than as a high-growth asset. Generic entry, limited ingredient differentiation, and the absence of separately reported brand revenue constrain its valuation.
References
-
U.S. Food and Drug Administration. (2017). Taytulla prescribing information and approval history, NDA 208304. FDA Drugs@FDA.
-
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 9,192,673: Pharmaceutical compositions comprising ethinyl estradiol and norethindrone acetate. Washington, DC: U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Allergan plc. (2019). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Dublin, Ireland.
-
AbbVie Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. North Chicago, IL.
